Druglikeness
- Druglikeness is a fundamental concept in drug discovery and development that refers to the likelihood of a chemical compound to possess the necessary properties to become a safe and effective medication.
- It involves the assessment of a compound's structural and physicochemical properties to determine its potential as a drug candidate.
- The concept of druglikeness helps researchers and pharmaceutical companies prioritize compounds for further development and increase the probability of successfully bringing new medications to the market.
Key Principles of Druglikeness[edit | edit source]
Several key principles govern druglikeness assessments:
- Molecular Size and Complexity: Drug candidates should have a molecular size and complexity that allows them to be easily synthesized and modified, while still having sufficient specificity for the drug target.
- Physicochemical Properties: Drug candidates should exhibit desirable physicochemical properties, including lipophilicity, solubility, and permeability, to facilitate their absorption, distribution, metabolism, and excretion (ADME) in the body.
- Bioavailability: Drug candidates should have adequate bioavailability, meaning they can reach the target site in sufficient concentrations to exert a therapeutic effect.
- Toxicity and Safety: Drug candidates should have a favorable safety profile, with low toxicity and minimal adverse effects.
- Target Specificity: Drug candidates should selectively interact with the intended drug target, minimizing interactions with off-target proteins to reduce the risk of side effects.
Evaluation of Druglikeness[edit | edit source]
Assessing druglikeness involves various computational and experimental methods:
- Lipinski's Rule of Five: Lipinski's Rule of Five is a widely used guideline that predicts druglikeness based on four criteria: molecular weight, lipophilicity (logP), hydrogen bond donors, and hydrogen bond acceptors. Compounds that violate more than one of these criteria are considered less likely to be orally bioavailable.
- Molecular Descriptors: Computational methods use various molecular descriptors, such as molecular weight, logP, polar surface area (PSA), and hydrogen bond donors/acceptors, to assess druglikeness.
- ADME Properties: Predictive models evaluate a compound's ADME properties, such as solubility, permeability, metabolic stability, and potential for drug-drug interactions.
- Toxicity Prediction: In silico models and in vitro assays help predict a compound's potential toxicity and safety profile.
Significance in Drug Development[edit | edit source]
Druglikeness is a crucial concept in drug development for several reasons:
- Lead Optimization: Assessing druglikeness guides medicinal chemists in modifying chemical structures to enhance a compound's drug-like properties while retaining its activity against the target.
- Candidate Prioritization: Druglikeness assessments allow researchers to prioritize compounds with the highest potential for success in preclinical and clinical development.
- Resource Allocation: Focusing resources on drug candidates with favorable druglikeness properties increases the efficiency of the drug development process and reduces the risk of costly failures.
- Regulatory Approval: Considering druglikeness early in drug development helps identify compounds that are more likely to meet regulatory requirements for safety and efficacy.
- Ethical Considerations: Prioritizing drug candidates with better druglikeness properties may reduce the use of animals in preclinical studies and human subjects in clinical trials.
Conclusion[edit | edit source]
- Druglikeness is a fundamental concept that plays a crucial role in drug discovery and development.
- By assessing the structural and physicochemical properties of chemical compounds, researchers can prioritize drug candidates with the highest likelihood of success and increase the efficiency of the drug development process.
- Ultimately, druglikeness assessments contribute to the identification of safe and effective medications that can improve patient outcomes and address unmet medical needs.
See also[edit | edit source]
- Lipinski's rule of five (RO5)
- Fragment-based lead discovery (FBLD)
References[edit | edit source]
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23(1-3):3-25. doi:10.1016/s0169-409x(96)00423-1.
- Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat Rev Drug Discov. 2011;10(4):307-317. doi:10.1038/nrd3410.
- Doak BC, Zheng J, Dobritzsch D, Kihlberg J. How beyond rule of 5 drugs and clinical candidates bind to their targets. J Med Chem. 2015;58(21):8313-8324. doi:10.1021/acs.jmedchem.5b00954.
- Need help finding a doctor or specialist anywhere in the world? WikiMD's DocFinder can help with millions of doctors!
This article is a stub. Help WikiMD grow by registering to expand it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Deepika vegiraju